BAM
CYTK icon

Belpointe Asset Management’s Cytokinetics CYTK Stock Holding History

Belpointe Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-786
Closed -$27.7K – 1186
2023
Q1 		$27.7K Buy
786
+340
+76% +$13.9K ﹤0.01% 2109
2022
Q4 		$20.4K Buy
+446
New +$19.2K ﹤0.01% 2167

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Belpointe Asset Management's CYTK Position: Q2 2023 in Review

Belpointe Asset Management sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 786 shares — an estimated $27.7K sold.

Belpointe Asset Management first reported a position in CYTK in Q4 2022 and held it in 2 quarters. The position peaked at $27.7K in Q1 2023. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

  • Belpointe Asset Management reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 786 Cytokinetics shares in Q2 2023, an estimated $27.7K.
  • Belpointe Asset Management first reported a position in Cytokinetics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Cytokinetics position peaked at $27.7K in Q1 2023.
  • 253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.